An in situ and in vitro investigation of cytoplasmic TDP-43 inclusions reveals the absence of a clear amyloid signature

References

• Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602–611.
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130–133.
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61(5):427–434.
   PubMed Web of Science ®Google Scholar
• Tan CF, Eguchi H, Tagawa A, et al. TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol. 2007;113(5):535–542.
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74(1):20–38.
   PubMed Web of Science ®Google Scholar
• Prasad A, Bharathi V, Sivalingam V, et al. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front Mol Neurosci. 2019;12:25.
   PubMed Web of Science ®Google Scholar
• Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4:3.
   PubMed Web of Science ®Google Scholar
• Liscic RM, Grinberg LT, Zidar J, et al. ALS and FTLD: two faces of TDP-43 proteinopathy. Eur J Neurol. 2008;15(8):772–780.
   PubMed Web of Science ®Google Scholar
• Higashi S, Iseki E, Yamamoto R, et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer’s disease and dementia with lewy bodies. Brain Res. 2007;1184:284–294.
   PubMed Web of Science ®Google Scholar
• Amador-Ortiz C, Lin WL, Ahmed Z, et al. TDP-43 immunoreactivity in hippocampal sclerosis and alzheimer’s disease. Ann Neurol. 2007;61(5):435–445.
   PubMed Web of Science ®Google Scholar
• Nakashima-Yasuda H, Uryu K, Robinson J, et al. Co-morbidity of TDP-43 proteinopathy in lewy body related diseases. Acta Neuropathol. 2007;114(3):221–229.
   PubMed Web of Science ®Google Scholar
• Schwab C, Arai T, Hasegawa M, et al. Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of huntington disease. J Neuropathol Exp Neurol. 2008;67(12):1159–1165.
   PubMed Web of Science ®Google Scholar
• Baloh RH. TDP-43: the relationship between protein aggregation and neurodegeneration in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. FEBS J. 2011;278(19):3539–3549.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Arai T, Nonaka T, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008;64(1):60–70.
   PubMed Web of Science ®Google Scholar
• Igaz LM, Kwong LK, Xu Y, et al. Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol. 2008;173(1):182–194.
   PubMed Web of Science ®Google Scholar
• Halliday G, Bigio EH, Cairns NJ, et al. Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. Acta Neuropathol. 2012;124(3):373–382.
   PubMed Web of Science ®Google Scholar
• Lee EB, Lee VM, Trojanowski JQ. Gains or losses: molecular mechanisms of TDP-43-mediated neurodegeneration. Nat Rev Neurosci. 2011;13(1):38–50.
   PubMed Web of Science ®Google Scholar
• Cascella R, Capitini C, Fani G, et al. Quantification of the relative contributions of loss-of-function and gain-of-function mechanisms in TAR DNA-binding protein 43 (TDP-43) proteinopathies. J Biol Chem. 2016;291(37):19437–19448.
   PubMed Web of Science ®Google Scholar
• Suk TR, Rousseaux MWC. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegener. 2020;15(1):45.
   PubMed Web of Science ®Google Scholar
• Vivoli Vega M, Nigro A, Luti S, et al. Isolation and characterization of soluble human full-length TDP-43 associated with neurodegeneration. FASEB J. 2019;33(10):10780–10793.
   PubMed Web of Science ®Google Scholar
• Chiti F, Dobson CM. Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu Rev Biochem. 2017;86:27–68.
   PubMed Web of Science ®Google Scholar
• Dapson RW. Amyloid from a histochemical perspective. A review of the structure, properties and types of amyloid, and a proposed staining mechanism for Congo red staining. Biotech Histochem. 2018;93(8):543–556.
   PubMed Web of Science ®Google Scholar
• Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid. 2020;27(4):217–222.
   PubMed Web of Science ®Google Scholar
• Giordana MT, Piccinini M, Grifoni S, et al. TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis. Brain Pathol. 2010;20(2):351–360.
   PubMed Web of Science ®Google Scholar
• Braak H, Ludolph A, Thal DR, et al. Amyotrophic lateral sclerosis: dash-like accumulation of phosphorylated TDP-43 in somatodendritic and axonal compartments of somatomotor neurons of the lower brainstem and spinal cord. Acta Neuropathol. 2010;120(1):67–74.
   PubMed Web of Science ®Google Scholar
• Lin WL, Dickson DW. Ultrastructural localization of TDP-43in filamentous neuronal inclusions in various neurodegenerative diseases. Acta Neuropathol. 2008;116(2):205–213.
   PubMed Web of Science ®Google Scholar
• Thorpe JR, Tang H, Atherton J, et al. Fine structural analysis of the neuronal inclusions of frontotemporal lobar degeneration with TDP-43 proteinopathy. J Neural Transm. 2008;115(12):1661–1671.
   PubMed Web of Science ®Google Scholar
• Robinson JL, Geser F, Stieber A, et al. TDP-43 skeins show properties of amyloid in a subset of ALS cases. Acta Neuropathol. 2013;125(1):121–131.
   PubMed Web of Science ®Google Scholar
• Nonaka T, Masuda-Suzukake M, Arai T, et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 2013;4(1):124–134.
   PubMed Web of Science ®Google Scholar
• Arseni D, Hasegawa M, Murzin AG, et al. Structure of pathological TDP-43 filaments from ALS with FTLD. Nature. 2022;601(7891):139–143.
   PubMed Web of Science ®Google Scholar
• Sun Y, Medina Cruz A, Hadley KC, et al. Physiologically important electrolytes as regulators of TDP-43 aggregation and droplet-phase behavior. Biochemistry. 2019;58(6):590–607.
   PubMed Web of Science ®Google Scholar
• Kerman A, Liu HN, Croul S, et al. Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neuropathol. 2010;119(3):335–344.
   PubMed Web of Science ®Google Scholar
• Cairns NJ, Neumann M, Bigio EH, et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol. 2007;171(1):227–240.
   PubMed Web of Science ®Google Scholar
• Capitini C, Conti S, Perni M, et al. TDP-43 inclusion bodies formed in bacteria are structurally amorphous, non-amyloid and inherently toxic to neuroblastoma cells. PLOS One. 2014;9(1):e86720.
   PubMed Web of Science ®Google Scholar
• Laferrière F, Maniecka Z, Pérez-Berlanga M, et al. TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat Neurosci. 2019;22(1):65–77.
   PubMed Web of Science ®Google Scholar
• Bigio EH, Wu JY, Deng HX, et al. Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. Acta Neuropathol. 2013;125(3):463–465.
   PubMed Web of Science ®Google Scholar
• Chang A, Xiang X, Wang J, et al. Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases. Cell. 2022;185(8):1346–1355.e15.
   PubMed Web of Science ®Google Scholar
• Jiang YX, Cao Q, Sawaya MR, et al. Amyloid fibrils in FTLD-TDP are composed of TMEM106B and not TDP-43. Nature. 2022;605(7909):304–309.
   PubMed Web of Science ®Google Scholar
• Schweighauser M, Arseni D, Bacioglu M, et al. Age-dependent formation of TMEM106B amyloid filaments in human brains. Nature. 2022;605(7909):310–314.
   PubMed Web of Science ®Google Scholar
• Cashman NR, Durham HD, Blusztajn JK, et al. Neuroblastoma × spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev Dyn. 1992;194(3):209–221.
   PubMed Web of Science ®Google Scholar
• Cascella R, Fani G, Capitini C, et al. Quantitative assessment of the degradation of aggregated TDP-43 mediated by the ubiquitin proteasome system and macroautophagy. Faseb J. 2017;31(12):5609–5624.
   PubMed Web of Science ®Google Scholar
• Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337–351.
   PubMed Web of Science ®Google Scholar
• Tampellini D, Magrane J, Takahashi RH, et al. Internalized antibodies to the abeta domain of APP reduce neuronal abeta and protect against synaptic alterations. J Biol Chem. 2007;282(26):18895–18906.
   PubMed Web of Science ®Google Scholar
• Bigi A, Loffredo G, Cascella R, et al. Targeting pathological amyloid aggregates with conformation-sensitive antibodies. Curr Alzheimer Res. 2020;17(8):722–734.
   PubMed Web of Science ®Google Scholar
• Dahlgren KN, Manelli AM, Stine WB Jr., et al. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem. 2002;277(35):32046–32053.
   PubMed Web of Science ®Google Scholar
• Pretorius E, Page MJ, Hendricks L, et al. Both lipopolysaccharide and lipoteichoic acids potently induce anomalous fibrin amyloid formation: assessment with novel Amytracker™ stains. J R Soc Interface. 2018;15(139):20170941.
   PubMed Web of Science ®Google Scholar
• Ghadami SA, Hossein-Pour Z, Khodarahmi R, et al. Synthesis and in vitro characterization of some benzothiazole-and benzofuranone-derivatives for quantification of fibrillar aggregates and inhibition of amyloid-mediated peroxidase activity. Med Chem Res. 2013;22(1):115–126.
   Web of Science ®Google Scholar
• Ghadami SA, Shevidi S, Hosseinzadeh L, et al. Synthesis and in vitro quantification of amyloid fibrils by barbituric and thiobarbituric acid-based chromene derivatives. Biophys Chem. 2021;269:106522.
   PubMed Web of Science ®Google Scholar
• Martin J, Letellier G, Marin A, et al. Protein secondary structure assignment revisited: a detailed analysis of different assignment methods. BMC Struct Biol. 2005;5:17.
   PubMed Web of Science ®Google Scholar
• Perez MAS, Bassani-Sternberg M, Coukos G, et al. Analysis of secondary structure biases in naturally presented HLA-I ligands. Front Immunol. 2019;10:2731.
   PubMed Web of Science ®Google Scholar
• Chiti F, Taddei N, Stefani M, et al. Reduction of the amyloidogenicity of a protein by specific binding of ligands to the native conformation. Protein Sci. 2001;10(4):879–886.
   PubMed Web of Science ®Google Scholar
• Rygula A, Majzner K, Marzec KM, et al. Raman spectroscopy of proteins: a review. J Raman Spectrosc. 2013;44(8):1061–1076.
   Web of Science ®Google Scholar
• Atlante A, Calissano P, Bobba A, et al. Cytochrome c is released from mitochondria in a reactive oxygen species (ROS)-dependent fashion and can operate as a ROS scavenger and as a respiratory substrate in cerebellar neurons undergoing excitotoxic death. J Biol Chem. 2000;275(47):37159–37166.
   PubMed Web of Science ®Google Scholar
• Chen Z, Liu J, Tian L, et al. Raman micro-spectroscopy monitoring of cytochrome c redox state in Candida utilis during cell death under low-temperature plasma-induced oxidative stress. Analyst. 2020;145(11):3922–3930.
   PubMed Web of Science ®Google Scholar
• Ami D, Lavatelli F, Rognoni P, et al. In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study. Sci Rep. 2016;6:29096.
   PubMed Web of Science ®Google Scholar
• Ami D, Mereghetti P, Leri M, et al. A FTIR microspectroscopy study of the structural and biochemical perturbations induced by natively folded and aggregated transthyretin in HL-1 cardiomyocytes. Sci Rep. 2018;8(1):12508.
   PubMedGoogle Scholar
• LeVine H. III. Thioflavine T interaction with synthetic alzheimer’s disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993;2(3):404–410.
   PubMed Web of Science ®Google Scholar
• Xue C, Yuwen Lin T, Chang D, et al. Thioflavin T as an amyloid dye: fibril quantification, optimal concentration and effect on aggregation. R Soc Open Sci. 2017;4(1):160696.
   PubMed Web of Science ®Google Scholar
• Chiti F, Bucciantini M, Capanni C, et al. Solution conditions can promote formation of either amyloid protofilaments or mature fibrils from the HypF N-terminal domain. Protein Sci. 2001;10(12):2541–2547.
   PubMed Web of Science ®Google Scholar
• Soldi G, Bemporad F, Torrassa S, et al. Amyloid formation of a protein in the absence of initial unfolding and destabilization of the native state. Biophys J. 2005;89(6):4234–4244.
   PubMed Web of Science ®Google Scholar
• Picotti P, De Franceschi G, Frare E, et al. Amyloid fibril formation and disaggregation of fragment 1-29 of apomyoglobin: insights into the effect of pH on protein fibrillogenesis. J Mol Biol. 2007;367(5):1237–1245.
   PubMed Web of Science ®Google Scholar
• Motamedi-Shad N, Monsellier E, Torrassa S, et al. Kinetic analysis of amyloid formation in the presence of heparan sulfate: faster unfolding and change of pathway. J Biol Chem. 2009;284(43):29921–29934.
   PubMed Web of Science ®Google Scholar
• Sicorello A, Torrassa S, Soldi G, et al. Agitation and high ionic strength induce amyloidogenesis of a folded PDZ domain in native conditions. Biophys J. 2009;96(6):2289–2298.
   PubMed Web of Science ®Google Scholar
• Shokri MM, Ahmadian S, Bemporad F, et al. Amyloid fibril formation by a normally folded protein in the absence of denaturants and agitation. Amyloid. 2013;20(4):226–232.
   PubMed Web of Science ®Google Scholar
• Ramshini H, Tayebee R, Bigi A, et al. Identification of novel 1,3,5-triphenylbenzene derivative compounds as inhibitors of hen lysozyme amyloid fibril formation. Int J Mol Sci. 2019;20(22):5558.
   PubMed Web of Science ®Google Scholar
• Medinas DB, Rozas P, Martínez Traub F, et al. Endoplasmic reticulum stress leads to accumulation of wild-type SOD1 aggregates associated with sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2018;115(32):8209–8214.
   PubMed Web of Science ®Google Scholar
• Capitini C, Fani G, Vivoli Vega M, et al. Full-length TDP-43 and its C-terminal domain form filaments in vitro having non-amyloid properties. Amyloid. 2021;28(1):56–65.
   PubMed Web of Science ®Google Scholar
• Hintermayer MA, Volkening K, Moszczynski AJ, et al. Tau protein phosphorylation at thr 175 initiates fibril formation via accessibility of the N-terminal phosphatase-activating domain. J Neurochem. 2020;155(3):313–326.
   PubMed Web of Science ®Google Scholar
• Roberti MJ, Bertoncini CW, Klement R, et al. Fluorescence imaging of amyloid formation in living cells by a functional, tetracysteine-tagged alpha-synuclein. Nat Methods. 2007;4(4):345–351.
   PubMed Web of Science ®Google Scholar
• Ko L-W, Ko H-HC, Lin W-L, et al. Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells. J Neuropathol Exp Neurol. 2008;67(11):1084–1096.
   PubMed Web of Science ®Google Scholar
• Abedini A, Raleigh DP. A critical assessment of the role of helical intermediates in amyloid formation by natively unfolded proteins and polypeptides. Protein Eng Des Sel. 2009;22(8):453–459.
   PubMed Web of Science ®Google Scholar
• Johnson BS, Snead D, Lee JJ, et al. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosislinked mutations accelerate aggregation and increase toxicity. J Biol Chem. 2009;284(30):20329–20339.
   PubMed Web of Science ®Google Scholar
• Furukawa Y, Kaneko K, Watanabe S, et al. A seeding reaction recapitulates intracellular formation of sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions. J Biol Chem. 2011;286(21):18664–18672.
   PubMed Web of Science ®Google Scholar
• Carlomagno Y, Zhang Y, Davis M, et al. Casein kinase II induced polymerization of soluble TDP-43 into filaments is inhibited by heat shock proteins. PLOS One. 2014;9(3):e90452.
   PubMed Web of Science ®Google Scholar
• Fang YS, Tsai KJ, Chang YJ, et al. Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients. Nat Commun. 2014;5:4824.
   PubMed Web of Science ®Google Scholar
• Staderini T, Bigi A, Mongiello D, Cecchi C, Chiti F. Biophysical Characterization of Full Length TAR DNA Binding Protein (TDP-43) Phase Separation. Protein Sci. 2022; e4509.
   Google Scholar
• Esposto JC, Martic S. Phosphorylated TAR DNA-binding protein-43: aggregation and antibody-based inhibition. Biochim Biophys Acta Mol Basis Dis. 2021;1867(12):166234.
   PubMed Web of Science ®Google Scholar
• Doke AA, Jha SK. Effect of in vitro solvation conditions on inter- and intramolecular assembly of Full-Length TDP-43. J Phys Chem B. 2022;126(26):4799–4813.
   PubMedGoogle Scholar
• Lim L, Wei Y, Lu Y, et al. ALS-causing mutations significantly perturb the self-assembly and interaction with nucleic acid of the intrinsically disordered Prion-like domain of TDP-43. PLOS Biol. 2016;14(1):e1002338.
   PubMed Web of Science ®Google Scholar
• Jiang LL, Che MX, Zhao J, et al. Structural transformation of the amyloidogenic core region of TDP-43 protein initiates its aggregation and cytoplasmic inclusion. J Biol Chem. 2013;288(27):19614–19624.
   PubMed Web of Science ®Google Scholar
• Guo W, Chen Y, Zhou X, et al. An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nat Struct Mol Biol. 2011;18(7):822–830.
   PubMed Web of Science ®Google Scholar
• Chen AK, Lin RY, Hsieh EZ, et al. Induction of amyloid fibrils by the C-terminal fragments of TDP-43 in amyotrophic lateral sclerosis. J Am Chem Soc. 2010;132(4):1186–1187.
   PubMed Web of Science ®Google Scholar
• Cao Q, Boyer DR, Sawaya MR, et al. Cryo-EM structures of four polymorphic TDP-43 amyloid cores. Nat Struct Mol Biol. 2019;26(7):619–627.
   PubMed Web of Science ®Google Scholar
• Guenther EL, Ge P, Trinh H, et al. Atomic-level evidence for packing and positional amyloid polymorphism by segment from TDP-43 RRM2. Nat Struct Mol Biol. 2018;25(4):311–319.
   PubMed Web of Science ®Google Scholar
• Li Q, Babinchak WM, Surewicz WK. Cryo-EM structure of amyloid fibrils formed by the entire low complexity domain of TDP-43. Nat Commun. 2021;12(1):1620.
   PubMed Web of Science ®Google Scholar
• Ramshini H, Parrini C, Relini A, et al. Large proteins have a great tendency to aggregate but a low propensity to form amyloid fibrils. PLOS One. 2011;6(1):e16075.
   PubMed Web of Science ®Google Scholar
• Cascella R, Bigi A, Riffert DG, et al. A quantitative biology approach correlates neuronal toxicity with the largest inclusions of TDP-43. Sci Adv. 2022;8(30):eabm6376.
   PubMed Web of Science ®Google Scholar